The Cholesterol Lowering Stack: Psyllium, Plant Sterols, Oat Beta-Glucan, and Bergamot
Statins remain the LDL-lowering intervention with the strongest cardiovascular outcome data. Supplements have a defined role for adults who don't yet meet treatment thresholds, are statin-intolerant, or want adjunctive reduction. Four anchor a defensible stack — three with formal FDA or EFSA health claims, one with strong RCT signal: psyllium, plant sterols, beta-glucan">beta-glucan">oat beta-glucan, and bergamot polyphenols.
Layer 1: Psyllium Husk, 10 g Daily
Psyllium has an FDA-authorized cardiovascular health claim. A 2018 meta-analysis of 28 RCTs found 10 g/day reduced LDL by ~7% and total cholesterol by ~6% over 8+ weeks. Effect is independent of dietary changes and additive to statin therapy. Take in divided doses with adequate fluid. See psyllium piece.
Layer 2: Plant Sterols (Beta-Sitosterol Complex), 2 g Daily
Plant sterols compete with cholesterol for intestinal absorption. The European Atherosclerosis Society endorses 2 g daily for LDL reduction of 8-10%. Best taken with the largest meal. EFSA has authorized a regulatory-grade health claim. See beta-sitosterol piece.
Layer 3: Oat Beta-Glucan, 3 g Daily
Oat beta-glucan has an FDA-authorized health claim. 3 g daily reduces LDL by ~5-7% via bile-acid binding and induced hepatic cholesterol uptake. Sources: oat bran (~1 g per 40 g serving) or standalone beta-glucan supplement. See oat beta-glucan piece.
Layer 4: Bergamot Polyphenols (BPF), 500–1,000 mg Daily
Bergamot polyphenol fraction has the strongest single-supplement LDL signal outside red yeast rice. Pooled trial data shows LDL reductions of 15-25% at 500-1,000 mg daily over 12 weeks. Mechanism includes HMG-CoA reductase inhibition (similar to statins but with smaller magnitude). See bergamot piece.
Layer 5 (Optional): Red Yeast Rice — Treat as a Statin Substitute, Not Just a Supplement
Red yeast rice contains monacolin K — the same molecule as prescription lovastatin. Effective LDL reductions of 15-25%. The catch: unregulated supply quality, all the same statin side effects, and serious supply-quality variability. Banned in some EU markets. If used, treat as a statin: monitor LFTs, take CoQ10 alongside, don't combine with prescription statins. See red yeast rice piece.
What NOT to Take
Niacin's CV outcome data is poor (AIM-HIGH, HPS2-THRIVE both null). Skip policosanol — large independent trials are null. Avoid garlic as a primary LDL intervention — effect too small to matter. Skip "lipid support" multi-herb formulas. Don't replace statin therapy in adults with established ASCVD, LDL ≥190 mg/dL, or diabetes age 40+.
How to Run the Stack
Get baseline lipid panel + ASCVD risk calculator. For ASCVD risk <7.5% with LDL 100-160 mg/dL: layer psyllium 10 g + plant sterols 2 g + oat beta-glucan 3 g daily for 12 weeks. Re-test. Add bergamot 1,000 mg if additional reduction needed. Red yeast rice as step-up to lovastatin-equivalent if statin-intolerant. For ASCVD risk ≥7.5%: statin therapy is standard. See heart health stack.
Sources
- Jovanovski E, Yashpal S, Komishon A, et al. "Effect of psyllium fiber on LDL cholesterol and alternative lipid targets." American Journal of Clinical Nutrition, 2018;108(5):922-932. PMID: 30239559. DOI: 10.1093/ajcn/nqy115.
- Gylling H, Plat J, Turley S, et al. "Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease." Atherosclerosis, 2014;232(2):346-360. PMID: 24468148. DOI: 10.1016/j.atherosclerosis.2013.11.043.
- Whitehead A, Beck EJ, Tosh S, Wolever TM. "Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials." American Journal of Clinical Nutrition, 2014;100(6):1413-1421. PMID: 25411276. DOI: 10.3945/ajcn.114.086108.
- Mollace V, Sacco I, Janda E, et al. "Hypolipemic and hypoglycaemic activity of bergamot polyphenols." Fitoterapia, 2011;82(3):309-316. PMID: 21056640. DOI: 10.1016/j.fitote.2010.10.014.
- Becker DJ, Gordon RY, Halbert SC, et al. "Red yeast rice for dyslipidemia in statin-intolerant patients." Annals of Internal Medicine, 2009;150(12):830-839. PMID: 19528562. DOI: 10.7326/0003-4819-150-12-200906160-00006.